Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI – Research Report) today and set a price target of $7.00.

ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI’s AI models and wet lab ...

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

Fintel reports that on January 22, 2025, Needham initiated coverage of Absci (NasdaqGS:ABSI) with a Buy recommendation. Analyst Price Forecast Suggests 164.38% Upside As of December 23 ...

In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other medical AI stocks. Investments in the global healthcare industry have ramped up ...

In this article, we are going to take a look at where Absci (NASDAQ:ABSI) stands against other AI companies under $2 billion market cap. It’s clear that AI holds immense promise but it comes with ...

Absci (NASDAQ:ABSI) was rising after a media report on a $20M investment by the semiconductor company Advanced Micro Devices (NASDAQ:AMD) in the AI drug creation company. ABSI is trading +43.97% ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other ...

Walmart is giving its logo the first facelift in nearly two decades, rolling out a new identity that is a subtle nod to its past. The 61-year-old company unveiled Monday a refresh of its brand ...